APC is altered in 1.98% of central nervous system embryonal neoplasm patients [2].

APC is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain APC status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

CDK6 is altered in 1.3% of central nervous system embryonal neoplasm patients [2].

CDK6 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CTDNEP1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

CTNNB1 is altered in 8.66% of central nervous system embryonal neoplasm patients [2].

CTNNB1 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CTNNB1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

DDX3X is altered in 7.41% of central nervous system embryonal neoplasm patients [2].

DDX3X is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

GLI2 is altered in 7.45% of central nervous system embryonal neoplasm patients [2].

GLI2 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain GLI2 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

H3F3A is altered in 0.86% of central nervous system embryonal neoplasm patients [2].

H3F3A is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

IDH1 is altered in 1.98% of central nervous system embryonal neoplasm patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A is altered in 5.17% of central nervous system embryonal neoplasm patients [2].

KDM6A is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

KMT2C is altered in 2.44% of central nervous system embryonal neoplasm patients [2].

KMT2C is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain KMT2C status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

KMT2D is altered in 13.54% of central nervous system embryonal neoplasm patients [2].

KMT2D is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

LRP1B is altered in 4.88% of central nervous system embryonal neoplasm patients [2].

LRP1B is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain LRP1B status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

MDM4 is altered in 1.29% of central nervous system embryonal neoplasm patients [2].

MDM4 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

MYC is altered in 3.0% of central nervous system embryonal neoplasm patients [2].

MYC is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYC status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

MYCL is altered in 0.44% of central nervous system embryonal neoplasm patients [2].

MYCL is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYCL status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

MYCN is altered in 1.72% of central nervous system embryonal neoplasm patients [2].

MYCN is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

OTX2 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain OTX2 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

PPM1D is altered in 1.82% of central nervous system embryonal neoplasm patients [2].

PPM1D is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PPM1D status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

PTCH1 is altered in 13.48% of central nervous system embryonal neoplasm patients [2].

PTCH1 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

PTEN is altered in 3.53% of central nervous system embryonal neoplasm patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PVT1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

RELA is an inclusion eligibility criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RELA status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SHH status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

SMARCA4 is altered in 6.01% of central nervous system embryonal neoplasm patients [2].

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

SMO is altered in 5.93% of central nervous system embryonal neoplasm patients [2].

SMO is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMO status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

SNCAIP is altered in 3.57% of central nervous system embryonal neoplasm patients [2].

SNCAIP is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SNCAIP status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

SUFU is altered in 3.02% of central nervous system embryonal neoplasm patients [2].

SUFU is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SUFU status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

TERT is altered in 1.42% of central nervous system embryonal neoplasm patients [2].

TERT is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain TERT status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

TP53 is altered in 10.32% of central nervous system embryonal neoplasm patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

YAP1 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain YAP1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].

ZMYM3 is altered in 1.94% of central nervous system embryonal neoplasm patients [2].

ZMYM3 is an inclusion eligibility criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ZMYM3 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [3].